* Hims & Hers Health Inc is expected to show a rise in quarterly revenue when it reports results on May 6 for the period ending March 31 2024
* The San Francisco California-based company is expected to report a 41.7% increase in revenue to $270.382 million from $190.77 million a year ago, according to the mean estimate from 11 analysts, based on LSEG data.The company's guidance on February 26 2024, for the period ended March 31, was for revenue between $267.00 million and $272.00 million.
* LSEG's mean analyst estimate for Hims & Hers Health Inc is for earnings of 1 cent per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by about 6.3% in the last three months.
* Wall Street's median 12-month price target for Hims & Hers Health Inc is $16.00, above its last closing price of $11.26.
The company's guidance on February 26 2024 for the period ended March 31 was for Earnings before Interest, Taxes, Depreciation and Amortization of between USD267 million and USD27 million. Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.02 -0.02 0.01 Beat 153.3
Sep. 30 2023 -0.03 -0.03 -0.04 Missed -27.3
Jun. 30 2023 -0.05 -0.05 -0.03 Beat 44.7
Mar. 31 2023 -0.07 -0.07 -0.05 Beat 30
Dec. -0.07 -0.07 -0.05 Beat 25
31 2022
Sep. 30 2022 -0.10 -0.10 -0.09 Beat 11.8
Jun. 30 2022 -0.10 -0.10 -0.10 Met 1.6
Jan. 1 0001 -0.07 -0.07 -0.08 Missed -12.3
This summary was machine generated May 4 at 02:26 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments